Ichimaro Yamada

Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.

Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: February 01, 2016

Erratum to: Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans.

Erratum to: Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans.

Journal: European journal of clinical pharmacology

Published: January 16, 2016

Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans.

Plasma pharmacokinetics and synovial concentrations of S-flurbiprofen plaster in humans.

Journal: European journal of clinical pharmacology

Published: August 09, 2015

Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.

Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: July 25, 2014

Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine.

Evaluation of the potency of telaprevir and its metabolites as inhibitors of renal organic cation transporters, a potential mechanism for the elevation of serum creatinine.

Journal: Drug metabolism and pharmacokinetics

Published: January 07, 2014

Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.

Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.

Journal: Journal of the American Academy of Dermatology

Published: August 05, 2013

Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.

Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan.

Journal: The Journal of dermatology

Published: December 27, 2012

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon-alpha-2b and ribavirin in hepatitis C patients.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 29, 2012

Showing 1-8 of 8

Last Updated: 09/26/2026